Shares of Morepen Laboratories Ltd climbed over 2% to ₹48.81 in Monday’s trade after the company secured a major regulatory milestone. The Center for Drug Evaluation (CDE) under China’s National Medical Products Administration (NMPA) has approved Morepen’s Loratadine API, marking a strong entry into one of the world’s largest pharmaceutical markets.
Loratadine, a second-generation antihistamine used widely for treating allergies, hay fever, and urticaria, is already a significant export product for Morepen. The company commands over 80% market share in the US generics segment for Loratadine and has supplied it globally for more than 25 years.
This approval enhances Morepen’s global presence and unlocks a large potential market in China. The company, known for its robust API exports valued at ₹650 crore, already supplies products to 82 countries. It operates USFDA-approved manufacturing facilities in Masulkhana and Baddi.
Key Highlights:
-
Stock movement: Up 2.03%, now trading at ₹48.81
-
Previous close: ₹47.84
-
Day range: ₹47.85 – ₹48.88
-
Market cap: ₹26.58B
-
P/E ratio: 20.22
-
Avg. volume: 5.12M
With 167 patents, 27 USDMFs, 10 China IDLs, and a strong compliance track record, Morepen is now better positioned to expand across high-growth markets like China, the US, Europe, Japan, and Russia.
